Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Дата публикации: 30-07-2026 02:08:13

PARIS, France – July 30, 2026 – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD	0	15.69	28-05-2026
2	Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy	0	17.81	03-08-2026
3	Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks	0	17.66	06-07-2026
4	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
5	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
6	Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA	0	13.35	22-06-2026
7	BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer	0	13.23	07-08-2026
8	AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile	0	19.85	10-08-2026
9	Sobi Receives Complete Response Letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)	0	9.15	26-06-2026
10	Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	0	13.95	26-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 18.01. Источник: www.drugs.com.